
https://www.science.org/content/blog-post/good-stuff-and-bad-stuff
# Good Stuff and Bad Stuff (January 2007)

## 1. SUMMARY

This article is not a commentary about biotechnology science or industry trends - it's a meta-discussion piece where the author (appearing to be a science blogger) poses two open questions to their industrial readership about pharmaceutical/biotech company research cultures. The author solicits anonymous feedback on: (1) what one thing about their company's research culture they would change if they could, ranging from minor annoyances to "grave structural failures," and (2) what research-related aspect their company "really gets right," particularly seeking uncommon examples that other companies might learn from. The piece has an informal, conversational tone and explicitly references the author's personal situation of considering leaving one company for another.

## 2. HISTORY

This is a blog-style discussion prompt rather than a substantive commentary on biotechnology developments, so there are no subsequent scientific or regulatory developments to track. The article's format as an open-ended question soliciting anonymous reader responses means it doesn't advance specific claims about technology, drugs, or companies. No concrete companies, drugs, methods, or policies are mentioned that could be followed up on. The article is essentially ephemeral content - a discussion starter rather than analytical journalism.

## 3. PREDICTIONS

The article contains no predictions about biotechnology or pharmaceutical industry developments. It poses retrospective questions about current (at the time) company cultures, not forward-looking statements about scientific, clinical, or business outcomes.

## 4. INTEREST

Rating: **2/10**

This article is of very low interest for retrospective analysis purposes because it's fundamentally a discussion prompt rather than substantive commentary on biotechnology science, technology, or industry developments. It doesn't analyze any specific companies, drugs, scientific methods, or policy issues in the biotech/pharmaceutical sector. The content is entirely meta-discussion about research culture without addressing concrete biotechnological content that could be evaluated with benefit of hindsight. There are no scientific claims, predictions, or industry analyses to assess against subsequent developments.

While such discussion prompts might have been engaging for contemporary readers in industry, they provide no analytical value for understanding how biotechnology actually evolved or whether any claims held up over time, since no such claims were made.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20070107-good-stuff-and-bad-stuff.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_